Related Experiment Video
Updated: Apr 19, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Nintedanib: from discovery to the clinic
Gerald J Roth1, Rudolf Binder, Florian Colbatzky
1Department of Medicinal Chemistry; §Department of Drug Metabolism and Pharmacokinetics; ‡Department of Non-Clinical Drug Safety; ∥Department of Translational Medicine and Clinical Pharmacology; ⊥Department of Respiratory Diseases Research; and #Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma GmbH & Co. KG , 88397 Biberach an der Riss, Germany.
Nintedanib, a triple angiokinase inhibitor, effectively treats non-small cell lung cancer (NSCLC), ovarian cancer, and idiopathic pulmonary fibrosis (IPF). This review details its preclinical and clinical development, highlighting significant efficacy in phase III studies.
Area of Science:
- Pharmacology
- Oncology
- Pulmonology
Background:
- Nintedanib is an oral small-molecule tyrosine kinase inhibitor targeting key pathways in angiogenesis and fibrosis.
- It inhibits vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR) families, among others.
Purpose of the Study:
- To provide a comprehensive review of nintedanib's preclinical and clinical research.
- To summarize the drug discovery process and latest clinical trial data for nintedanib.
Main Methods:
- Literature review of preclinical studies.
- Analysis of clinical trial data from phase III studies.
Main Results:
- Nintedanib demonstrated significant efficacy in treating non-small cell lung cancer (NSCLC).
- Nintedanib showed significant efficacy in treating ovarian cancer.
- Nintedanib demonstrated significant efficacy in treating idiopathic pulmonary fibrosis (IPF).
Conclusions:
- Nintedanib is a clinically validated therapeutic agent for NSCLC, ovarian cancer, and IPF.
- The review consolidates nintedanib's research and development journey, from discovery to clinical application.
Related Concept Videos
Drug Discovery: Overview
Clinical Trials: Overview
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Clinical Trials
There are four phases in a clinical trial. A phase one...

